While the pooled HR for female patients was only slightly higher than the one observed in males, the OS benefit did not reach statistical significance in females (pooled HR 0.85, 95% CI 0.70–1.03; Fig. 1 ).
← all excerpts
A meta-analysis and real-world cohort study on the sex-related differences in efficacy and safety of immunotherapy for hepatocellular carcinoma.
1
—
—